StockNews.AI
BCRX
StockNews.AI
190 days

BioCryst to Report Fourth Quarter 2024 Financial Results on February 24

1. BCRX will report Q4 2024 results on February 24, 2025. 2. A conference call and webcast will follow the results announcement. 3. BCRX focuses on rare diseases with innovative therapies like ORLADEYO®.

Earnings
+2.58%Current Return
VS
+0.63%S&P 500
$8.7202/10 07:04 AM EDTEvent Start
$8.94502/11 01:55 PM EDTLatest Updated
3m saved
Insight
Article

FAQ

Why Neutral?

The upcoming financial results are expected but not likely to cause significant volatility.

How important is it?

Earnings reports are crucial for assessing BCRX's financial health and outlook.

Why Short Term?

The results will provide immediate insights, affecting short-term investor sentiment.

Related Companies

BCRX
February 10, 2025 07:00 ET  | Source: BioCryst Pharmaceuticals, Inc. RESEARCH TRIANGLE PARK, N.C., Feb. 10, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its fourth quarter 2024 financial results on Monday, February 24, 2025. BioCryst management will host a conference call and webcast at 8:30 a.m. ET that day to discuss the financial results and provide a corporate update. The live call may be accessed by dialing 1-844-481-2942 for domestic callers and 1-412-317-1866 for international callers. A live webcast and replay of the call will be available online in the investors section of the company website at www.biocryst.com. About BioCryst Pharmaceuticals BioCryst Pharmaceuticals is a global biotechnology company with a deep commitment to improving the lives of people living with complement-mediated and other rare diseases. BioCryst leverages its expertise in structure-guided drug design to develop first-in-class or best-in-class small-molecule and protein therapeutics to target difficult-to-treat diseases. BioCryst has commercialized ORLADEYO® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of small-molecule and protein therapies. For more information, please visit www.biocryst.com or follow us on LinkedIn. BCRXW Contact:John Bluth+1 919 859 7910jbluth@biocryst.com

Related News